News | Intra-Aortic Balloon Pumps (IABP) | June 06, 2018

FDA Class 1 Recall of Maquet Datascope IABPs Due to Fluid Seepage

Maquet Datascope Corp. is recalling the CardioSave Hybrid Intra-aortic Balloon Pump (IABP).

The touchscreen Maquet Datascope CardioSave Hybrid Intra-aortic Balloon Pump (IABP) system console.

June 6, 2018 — Maquet Datascope Corp. said it is recalling the CardioSave Hybrid Intra-aortic Balloon Pump (IABP) due to fluid ingress that may affect device operation, interrupt or delay therapy. 

The U.S. Food and Drug Administration (FDA) issued a safety alert today that stated a design issue in the IABP can allow fluid (such as saline) to seep into the device. The fluid can cause corrosion of internal components such as the electronic circuit boards. The FDA said this can lead to device malfunction like sudden stops, which can cause a delay or interruption in therapy. The FDA said device failure may result in immediate and serious adverse health consequences, including death. 

The recall includes CardioSave Hybrid IABP part numbers: 0998-00-0800-XX, 0998-UC-0800-XX and cart 0997-00-1179 (excluding 0998-00-0800-83, 0998-UC-0800-83 & 0998-00-0800-75). The FDA said all lots are affected by this recall. 

The manufacturing dates include Dec 12, 2011 through April 25, 2018. The distribution dates were between March 6, 2012 to April 26, 2018. 

The CardioSave IABP is a cardiac assist device used with patients undergoing cardiac and non-cardiac surgery, and to treat patients with acute coronary syndrome or complications from heart failure, the FDA stated. 

Recommendations for Users: 

   • Never place fluids on top of the unit

   • Ensure that the saline container and tubing do not hang directly over the IABP

   • In case of accidental spillage, to wipe clean immediately and have the unit serviced to ensure no hazard exists.

   • In case of an interruption in therapy, the letter instructed users to:

   • Transfer the patient to an alternative IABP   

   • If an alternative IABP is unavailable, manually inflate the IAB with air or helium and immediately aspirate repeat every five minutes until either an alternate IABP is available or alternatively (i.e., if an alternative IABP is not available in a reasonable amount of time) the intra-aortic balloon catheter should be removed from the patient.

 

The FDA said affected customers will be contacted by Maquet Datascope Corp. to schedule on-site service of the IABP by a Maquet Datascope Corp. sales or service representative. The company anticipates having the protective top cover available by late June 2018.

U.S. customers wanting more information about this recall can contact Maquet Datascope Corp.’s Technical Support Department at 1-888-627-8383 (press option 3), Monday through Friday, between 8 a.m. and 6 p.m. Eastern Standard Time.

Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program at www.fda.gov/MedWatch/report.

Link to FDA Safety Alerts in 2018
 

Related Content

A large subgroup analysis of the VOYAGER PAD randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes was consistent regardless of whether a DCD was used. #TCT2020 #TCTconnect
Feature | Cath Lab | October 18, 2020
October 18, 2020 – A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benef
A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin capped fibrous atheroma (TCFA). #TCTconnect #TCT2020

A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin cap fibro-atheroma (TCFA).

News | Cath Lab | October 18, 2020
October 18, 2020 – Data from the...
The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions. #TCT2-0

The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions.

Feature | Cath Lab | October 16, 2020
October 15, 2020 — Shockwave Medical's Intravascular Lithotripsy (IVL) system to treat severely calcified coronary ar
Videos | Cath Lab | October 16, 2020
This is an example pf the Shockwave Medical Intravascular Lithotripsy (IVL) catheter system designed to break up heav
Videos | Cath Lab | July 15, 2020
Richard Botto, CVT, RCSA, chief cardiovascular technologist, division of cardiology, cardiac cath lab, offers an over
Videos | Cath Lab | July 13, 2020
The Vieussens’ arterial ring (VAR) is a connection between the conus artery and the left anterior descending (LAD) co
News | Cath Lab | July 06, 2020
July 6, 2020 — Black patients who undergo percutaneous coronary intervention (PCI) are at an increased risk for major
TCT cancels in-person meeting and goes virtual due to COVID-19
News | Cath Lab | May 27, 2020
May 27, 2020 — To ensure the health and safety of all attendees due to the ongoing COVID-19 (SARS-CoV-2) pandemic, th